VTv Therapeutics Shares Outstanding 2014-2021 | VTVT

VTv Therapeutics shares outstanding from 2014 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
VTv Therapeutics Annual Shares Outstanding
(Millions of Shares)
2020 47
2019 30
2018 12
2017 10
2016 10
2015 8
2014
2013
VTv Therapeutics Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 59
2021-03-31 56
2020-12-31 47
2020-09-30 48
2020-06-30 46
2020-03-31 43
2019-12-31 30
2019-09-30 32
2019-06-30 28
2019-03-31 23
2018-12-31 12
2018-09-30 12
2018-06-30 10
2018-03-31 10
2017-12-31 10
2017-09-30 10
2017-06-30 10
2017-03-31 10
2016-12-31 10
2016-09-30 10
2016-06-30 10
2016-03-31 9
2015-12-31 8
2015-09-30 8
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30 33
2013-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.152B $0.006B
vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company's drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29